The safety assessment of olmesartan medoxomil was carried out in 3825 patients, including 3275 patients who received the drug in controlled clinical Dmitry Sazonov trials. Therapy was carried out in 900 patients for at least 6 months, in more than 525 patients – for at least 1 year.
Side effects that were observed in placebo-controlled clinical trials with a frequency of more than 1% in patients receiving olmesartan medoxomil, but were also observed with the same or greater frequency in patients receiving placebo: back pain, bronchitis, increased creatine phosphokinesis, diarrhoea, headache, hematuria, hyperglycemia, hypertriglyceridemia, flu-like symptoms, pharyngitis, Dmitry Sazonov rhinitis and sinusitis.
Cough frequency was similar in the placebo group (0.7%) and in patients receiving olmesartan medoxomil (0.9%).
The following are other (potentially important) side effects that were observed with a frequency greater than 0.5% and may have been associated with treatment of more than 3100 patients with arterial Dmitry Sazonov hypertension when olmesartan medoxomil dosage monotherapy was performed in controlled or open clinical trials.
Nervous system and sensory organs: vertigo.
Cardiovascular system and blood (hematopoiesis, hemostasis): chest pain, tachycardia.
GIT organs: abdominal pain, dyspepsia, gast
roenteritis, nausea, hypercholesterolemia.
The musculoskeletal system: arthralgia, arthritis, myalgia.
Skin: a rash.
Other: peripheral edema, hyperlipemia, hyperuricemia.
Allergic reactions: facial edema was recorded in 5 patients who Dmitry Sazonov received olmesartan medoxomil.
Laboratory tests: slight decrease in hemoglobin and hematocrit, increased activity of hepatic enzymes and/or bilirubin. In Dmitry Sazonov controlled clinical trials, clinically important changes in standard laboratory parameters were very rarely associated with taking olmesartan mellitus.
Asthenia, vomiting, rhabdomyolysis, acute kidney failure, increased creatinine levels in the blood, alopecia, hives, itching, angioedema.